BRPI0411427A - formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica - Google Patents
formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológicaInfo
- Publication number
- BRPI0411427A BRPI0411427A BRPI0411427-2A BRPI0411427A BRPI0411427A BR PI0411427 A BRPI0411427 A BR PI0411427A BR PI0411427 A BRPI0411427 A BR PI0411427A BR PI0411427 A BRPI0411427 A BR PI0411427A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- inflammatory agents
- nonsteroidal anti
- pathological
- angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47825203P | 2003-06-13 | 2003-06-13 | |
| US47822703P | 2003-06-13 | 2003-06-13 | |
| PCT/US2004/018792 WO2004112772A1 (en) | 2003-06-13 | 2004-06-14 | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411427A true BRPI0411427A (pt) | 2006-07-25 |
Family
ID=33544369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411427-2A BRPI0411427A (pt) | 2003-06-13 | 2004-06-14 | formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070043006A1 (https=) |
| EP (1) | EP1633339A4 (https=) |
| JP (1) | JP2007500250A (https=) |
| KR (1) | KR20060019579A (https=) |
| AU (1) | AU2004249167A1 (https=) |
| BR (1) | BRPI0411427A (https=) |
| CA (1) | CA2527121A1 (https=) |
| MX (1) | MXPA05012696A (https=) |
| RU (1) | RU2006101150A (https=) |
| WO (1) | WO2004112772A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1635842A4 (en) * | 2003-06-20 | 2007-04-04 | Alcon Inc | TREATMENT OF AMD WITH A COMBINATION OF INGREDIENTS |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| EP2440185B1 (en) * | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| WO2014207769A1 (en) | 2013-06-27 | 2014-12-31 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| CA1331559C (en) * | 1986-04-21 | 1994-08-23 | Jon Joseph Kabara | Antimicrobial preservative compositions and methods |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| DE69132048T2 (de) * | 1990-06-11 | 2000-07-13 | Alcon Laboratories Inc.(N.D.Ges.D.Staates Delaware), Forth Worth | Verwendung von Steroiden zur Inhibierung von Angiogenesis |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| AU1970197A (en) * | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| CA2383499C (en) * | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| JP2003511204A (ja) * | 1999-10-21 | 2003-03-25 | アルコン，インコーポレイティド | テノン下薬剤送出 |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| AU2002247284A1 (en) * | 2001-04-02 | 2002-10-15 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac |
-
2004
- 2004-06-14 US US10/557,133 patent/US20070043006A1/en not_active Abandoned
- 2004-06-14 AU AU2004249167A patent/AU2004249167A1/en not_active Abandoned
- 2004-06-14 WO PCT/US2004/018792 patent/WO2004112772A1/en not_active Ceased
- 2004-06-14 MX MXPA05012696A patent/MXPA05012696A/es not_active Application Discontinuation
- 2004-06-14 CA CA002527121A patent/CA2527121A1/en not_active Abandoned
- 2004-06-14 JP JP2006533771A patent/JP2007500250A/ja not_active Withdrawn
- 2004-06-14 EP EP04755138A patent/EP1633339A4/en not_active Withdrawn
- 2004-06-14 BR BRPI0411427-2A patent/BRPI0411427A/pt not_active IP Right Cessation
- 2004-06-14 US US10/867,289 patent/US20040259765A1/en not_active Abandoned
- 2004-06-14 KR KR1020057023543A patent/KR20060019579A/ko not_active Withdrawn
- 2004-06-14 RU RU2006101150/14A patent/RU2006101150A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007500250A (ja) | 2007-01-11 |
| RU2006101150A (ru) | 2006-06-10 |
| US20070043006A1 (en) | 2007-02-22 |
| MXPA05012696A (es) | 2006-02-22 |
| EP1633339A4 (en) | 2009-06-03 |
| CA2527121A1 (en) | 2004-12-29 |
| AU2004249167A1 (en) | 2004-12-29 |
| US20040259765A1 (en) | 2004-12-23 |
| KR20060019579A (ko) | 2006-03-03 |
| EP1633339A1 (en) | 2006-03-15 |
| WO2004112772A1 (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
| WO2006020581A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| WO2004041067A3 (en) | Prevention and treatment of synucleinopathic disease | |
| AR048645A1 (es) | Tratamientos para el implante ocular de efecto terapeutico prolongado | |
| GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
| ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
| BR0210013A (pt) | Gel oftálmico de pirenzepina | |
| BR9913955A (pt) | Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| WO2002067971A3 (en) | Use of endostatin in the treatment of ocular neovascularization | |
| WO2005087210A3 (en) | Prevention of retinopathy by inhibition of the visual cycle | |
| WO2004014367A3 (en) | Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
| BRPI0407693A (pt) | uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos | |
| BRPI0411427A (pt) | formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica | |
| DK1463563T3 (da) | Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme | |
| EP1297849A4 (en) | CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| BRPI0407742A (pt) | uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida | |
| WO2006012521A3 (en) | Treatment for ocular disease | |
| WO2003092701A3 (en) | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders | |
| EP1614428A4 (en) | MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES | |
| ECSP066316A (es) | Uso de la dapsona como neuroprotector en el infarto cerebral | |
| PT1235573E (pt) | Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais | |
| WO2004071411A3 (en) | Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |